Results 111 to 120 of about 662,207 (147)

Barriers to SGLT2 inhibitor prescribing in primary care: findings from a cross-sectional questionnaire study in England. [PDF]

Clin Kidney J
Dattani R, Purssell N, Desilva R, Joshi M, Frankel AH, Ashrafian H, Darzi A, Tam FWK.   +7 more
europepmc   +1 more source

Kidney outcomes with SGLT2 inhibitor vs. DPP4 inhibitor use in older adults with diabetes

康永, 秀生, 10170, 10172, Yasunaga, Hideo, 岡田, 啓, Okada, Akira, 10171, 10174, 10173, 武田, 憲文, Node, Koichi, 南学, 正臣, 鈴木, 裕太, Morita, Hiroyuki, Suzuki, Yuta, 小室, 一成, スズキ, ユウタ, Komuro, Issei, 299, 西山, 成, Takeda, Norifumi, 小室, 仁, Ko, Toshiyuki, 10353, Nishiyama, Akira, 5713, 10850, 10852, Ieda, Masaki, Komuro, Jin, 金子, 英弘, 藤生, 克仁, 野出, 孝一, 森田, 啓行, 50954848, 家田, 真樹, 10902, Nangaku, Masaomi, 10165, Kaneko, Hidehiro, 10167, Fujiu, Katsuhito, 10862, 候, 聡志   +43 more
core  

Current practices of SGLT2 inhibitor use and ketone monitoring in intensive care units: A multicentre observational study. [PDF]

Crit Care Resusc
Sasaki T, Micallef S, Wang AY, Butt F, Hammond NE, Hardie M, Knowles S, Yokoo T, Gallagher M, George Institute for Global Health and the Australian and New Zealand Intensive Care Society Clinical Trials Group.   +9 more
europepmc   +1 more source

SGLT2 Inhibitor-Associated Changes in Urinary Volatile Organic Compounds in Diabetic Kidney Disease: A Comprehensive Study. [PDF]

Nephrology (Carlton)
Hara R, Yamahara H, Hirakawa Y, Hashiba T, Keying H, Tabata H, Nangaku M.   +6 more
europepmc   +1 more source

Long-Term Efficacy and Safety of GLP-1R Agonist and SGLT2 Inhibitor Therapy in the General Population: A Mendelian Randomization Study. [PDF]

Circ Genom Precis Med
Remala S, Liang L, Shah AM, Buckley LF.
europepmc   +1 more source

Diabetic Ketoacidosis Associated With Painless Thyroiditis in a Patient Treated With an SGLT2 Inhibitor. [PDF]

Case Rep Endocrinol
Aotani R, Ohkuma T, Oshiro A, Okamura K, Ago T.   +4 more
europepmc   +1 more source

Wound healing outcomes in diabetic kidney disease patients receiving SGLT2 inhibitor therapy: a prospective propensity score-matched cohort study. [PDF]

Front Endocrinol (Lausanne)
Zhang RR, Huang S, Wang X, Li X.
europepmc   +1 more source

Meta-analyses overgeneralize SGLT2 inhibitor effectiveness in population with low albuminuria, no diabetes, no heart failure and no atherovascular heart disease. [PDF]

Nephrol Dial Transplant
Murea M, Basile C, Piccoli GB.
europepmc   +1 more source

Efficacy and safety of SGLT2 inhibitor on insulin resistance and hyperglycemia in Werner syndrome-A case report. [PDF]

J Diabetes Investig
Yagi T, Aotani D, Hasegawa C, Shimizu Y, Koyama H, Maezawa Y, Yokote K, Tanaka T.   +7 more
europepmc   +1 more source

Cocktail Therapy Combining SGLT2 Inhibitor, Entresto, and Adipose-Derived Mesenchymal Stem Cells Prevents Abdominal Aortic Aneurysmal Complication Syndrome in Rodents. [PDF]

Acta Cardiol Sin
Sheu JJ, Chai HT, Chen YL, Ko SF, Sung PH, Yip HK.   +5 more
europepmc   +1 more source